Clinical trial
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
NCT00434850 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00434850 |
|---|---|
| Title | Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes |
| Official title | Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Biological, Drug |
| Interventions | Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept |
| Enrollment | 14 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Nov 1, 2013 |
| First posted | Feb 13, 2007 |
| Last update posted | Mar 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: